PEDIATRICS Vol. 84 No. 2 August 1989, pp. 404
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FEDER, H. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by FEDER, H. M., JR

In Reply: Treatment of Bacillus Infections

HENRY M. FEDER JR MD1

1 Depts of Family Medicine and Pediatrics, University of Connecticut, Health Center, Farmington, CT 06032

Dr Barson suggests that vancomycin should be used as empiric therapy for serious systemic and central nervous system Bacillus species infections pending susceptibility test results. This suggestion is based on the recent publication by Weber et al who reported that 54 strains of Bacillus cereus were susceptible to both vancomycin and chloramphenicol and that 35 strains on non-cereus Bacillus species were all susceptible to vancomycin; however, 14% of these 35 strains were resistant to chloramphenicol. Thus, chloramphenicol may be a poor choice for empiric therapy.